Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Fréneaux P, Diéras V, Thiéry JP, Sastre-Garau X. Vincent-Salomon A, et al. Among authors: dieras v. Br J Cancer. 2007 Feb 26;96(4):654-9. doi: 10.1038/sj.bjc.6603584. Epub 2007 Jan 30. Br J Cancer. 2007. PMID: 17262082 Free PMC article.
Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies.
de Cremoux P, Martin EC, Vincent-Salomon A, Dieras V, Barbaroux C, Liva S, Pouillart P, Sastre-Garau X, Magdelenat H. de Cremoux P, et al. Among authors: dieras v. Int J Cancer. 1999 Oct 8;83(2):157-61. doi: 10.1002/(sici)1097-0215(19991008)83:2<157::aid-ijc2>3.0.co;2-l. Int J Cancer. 1999. PMID: 10471520 Clinical Trial.
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.
Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P, Sastre-Garau X. Rozan S, et al. Among authors: dieras v. Int J Cancer. 1998 Feb 20;79(1):27-33. doi: 10.1002/(sici)1097-0215(19980220)79:1<27::aid-ijc6>3.0.co;2-y. Int J Cancer. 1998. PMID: 9495354
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
Pierga JY, Jouve M, Asselain B, Livartowski A, Beuzeboc P, Diéras V, Scholl S, Dorval T, Palangié T, Garcia-Giralt E, Pouillart P. Pierga JY, et al. Among authors: dieras v. Br J Cancer. 1998 May;77(9):1474-9. doi: 10.1038/bjc.1998.242. Br J Cancer. 1998. PMID: 9652764 Free PMC article. Clinical Trial.
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K, Asselain B, Vincent-Salomon A, Jouve M, Dieras V, Palangie T, Beuzeboc P, Dorval T, Pouillart P. Fizazi K, et al. Among authors: dieras v. Cancer. 1996 Apr 1;77(7):1315-23. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1315::AID-CNCR14>3.0.CO;2-4. Cancer. 1996. PMID: 8608509 Clinical Trial.
293 results